Compare Fidelity National Information Servcs Inc (FIS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Fidelity National Information Servcs Inc trades at $34.14 (market cap $17.71B), while Vertex Pharmaceuticals Incorporated trades at $510.9 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 7.2× Fidelity National Information Servcs Inc's market cap, and Fidelity National Information Servcs Inc pays a 5.13% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 88 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| FIS | VRTX | |
|---|---|---|
Market Cap | $17.71B | $127.55B |
Volume | 9,047,825 | 1,487,944 |
Sector | Technology | Health |
52-Week High | $68.57 | $557.96 |
52-Week Low | $32.44 | $407.37 |
Typical Hold Time | 88 Days | 120 Days |
Enterprise Value | $38.22B | $121.68B |
Dividend Yield | 5.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $33.82, up 1.2% today, with a bearish technical signal despite beating earnings estimates in two of the last three quarters. The stock shows attractive valuation metrics with a P/E of 5.27 and P/S of 1.46, while analyst consensus remains strongly bullish with a $47.15 price target. Recent business developments include multiple core banking platform wins and new embedded banking offerings, signaling growth momentum in financial technology services.
The outlook appears positive given FIS's improving profitability trajectory and strong analyst support, though investors should monitor debt levels and execution risks. With revenue projected to grow to $12.2B in 2026 and net income margin expanding to 27.64%, the stock offers fundamental upside potential if the company can maintain its competitive positioning in banking technology modernization.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
